{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:49:36Z","timestamp":1778676576087,"version":"3.51.4"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003356"],"award-info":[{"award-number":["82003356"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007128","name":"Natural Science Foundation of Shaanxi Province","doi-asserted-by":"publisher","award":["2019JQ-511"],"award-info":[{"award-number":["2019JQ-511"]}],"id":[{"id":"10.13039\/501100007128","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Vismodegib, an inhibitor of the Hedgehog signaling pathway, has been widely used in the treatment of advanced basal cell carcinoma. Given its critical role in managing advanced basal cell carcinoma and the relatively high rate of treatment discontinuation, it is crucial to comprehensively understand its safety profile in real-world settings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study analyzed all adverse event reports that identified vismodegib as the primary suspected drug since 2012 in the FDA Adverse Event Reporting System database. Disproportionality analysis was conducted using four algorithms: Reporting odds ratio, proportional reporting ratio, multi-item gamma Poisson shrinker, and Bayesian confidence propagation neural network to assess the safety profile of vismodegib in clinical practice. Additionally, this study employed the Weibull distribution to model the risk of adverse events over time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 7,733 adverse event reports associated with vismodegib were identified from the FDA Adverse Event Reporting System database. Data mining identified positive signals for on-label adverse events, such as muscle spasms, taste alterations, alopecia, fatigue, and weight decreased. Notably, potential off-label adverse events including squamous cell carcinoma, dehydration and dysphagia were also detected. The median time to onset for these adverse events was 69 days post-drug administration, highlighting the importance of close monitoring, particularly within the initial 2\u00a0months of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study provides valuable insights into the real-world safety profile of vismodegib. It not only confirms the known adverse events on the label, but also suggests several potential novel adverse events, thereby supporting a more informed and rational use of vismodegib in clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1497708","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T05:20:09Z","timestamp":1747372809000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database"],"prefix":"10.3389","volume":"16","author":[{"given":"Bingqing","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaidi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningyi","family":"Xian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Landong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiashu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dewu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1517\/14740338.2016.1167184","article-title":"Data mining spontaneous adverse drug event reports for safety signals in Singapore \u2013 a comparison of three different disproportionality measures","volume":"15","author":"Ang","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"B3","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ejca.2017.08.022","article-title":"Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial","volume":"86","author":"Basset-S\u00e9GUIN","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1001\/jamaophthalmol.2020.1539","article-title":"Outcomes of vismodegib for periocular locally advanced basal cell carcinoma from an open-label trial","volume":"138","author":"Ben Ishai","year":"2020","journal-title":"JAMA Ophthalmol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"100844","DOI":"10.1016\/j.eclinm.2021.100844","article-title":"Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: first results of a multicenter, open-label, phase 2 trial (VISMONEO study): neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma","volume":"35","author":"Bertrand","year":"2021","journal-title":"EClinicalMedicine"},{"key":"B6","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jaad.2017.03.038","article-title":"Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib","volume":"77","author":"Bhutani","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jid.2020.07.036","article-title":"Vismodegib efficacy in advanced basal cell carcinoma maintained with 8-week dose interruptions: a model-based evaluation","volume":"141","author":"Chanu","year":"2021","journal-title":"J. Investigative Dermatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"15215","DOI":"10.18632\/oncotarget.7714","article-title":"Improved therapy for neuroblastoma using a combination approach: superior efficacy with vismodegib and topotecan","volume":"7","author":"Chaturvedi","year":"2016","journal-title":"Oncotarget"},{"key":"B9","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1684\/ejd.2016.2747","article-title":"Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma","volume":"26","author":"Dika","year":"2016","journal-title":"Eur. J. Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/S1470-2045(17)30072-4","article-title":"Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial","volume":"18","author":"Dr\u00e9NO","year":"2017","journal-title":"Lancet Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1111\/jdv.16230","article-title":"Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion","volume":"34","author":"Dummer","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B13","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s40257-024-00870-3","article-title":"Evaluation of the tolerability of hedgehog pathway inhibitors in the treatment of advanced basal cell carcinoma: a narrative review of treatment strategies","volume":"25","author":"Farberg","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s13555-022-00864-1","article-title":"The association of alopecia areata-related emotional symptoms with work productivity and daily activity among patients with Alopecia areata","volume":"13","author":"Gandhi","year":"2023","journal-title":"Dermatol Ther. (Heidelb)"},{"key":"B15","volume-title":"ERIVEDGE\u00ae (vismodegib) capsules","year":"2023"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.jaad.2017.11.045","article-title":"Occurrence of vismodegib-induced cramps (muscular spasms) in the treatment of basal cell carcinoma: a prospective study in 30 patients","volume":"78","author":"Girard","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1517\/17460441.2014.920816","article-title":"Discovery and preclinical development of vismodegib","volume":"9","author":"Gould","year":"2014","journal-title":"Expert Opin. Drug Discov."},{"key":"B18","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/j.1365-2125.2012.04281.x","article-title":"Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects","volume":"74","author":"Graham","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"CD009647","DOI":"10.1002\/14651858.CD009647.pub2","article-title":"Clinical symptoms, signs and tests for identification of impending and current water-loss dehydration in older people","volume":"2015","author":"Hooper","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1186\/s12885-022-09940-3","article-title":"Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25 years","volume":"22","author":"Hu","year":"2022","journal-title":"BMC Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.jaad.2016.04.063","article-title":"Practical management of the adverse effects of Hedgehog pathway inhibitor therapy for basal cell carcinoma","volume":"76","author":"Jacobsen","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.37765\/ajmc.2020.42769","article-title":"Insomnia overview: epidemiology, pathophysiology, diagnosis and monitoring, and nonpharmacologic therapy","volume":"26","author":"Julie","year":"2020","journal-title":"Am. J. Manag. Care"},{"key":"B23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.hoc.2018.09.004","article-title":"Basal cell carcinoma review","volume":"33","author":"Kim","year":"2019","journal-title":"Hematology\/Oncology Clin. N. Am."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e73559","DOI":"10.7759\/cureus.73559","article-title":"A large basal cell carcinoma treated with hedgehog inhibitor: a case report","volume":"16","author":"Koch","year":"2024","journal-title":"Cureus"},{"key":"B25","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jaad.2016.02.1235","article-title":"Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC)","volume":"75","author":"Kwon","year":"2016","journal-title":"J. Am. Acad. Dermatology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.18632\/oncotarget.28145","article-title":"Using drug scheduling to manage adverse events associated with hedgehog pathway inhibitors for basal cell carcinoma","volume":"12","author":"Lear","year":"2021","journal-title":"Oncotarget"},{"key":"B27","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s13105-023-00982-0","article-title":"Role of sonic hedgehog signaling pathway in the regulation of ion channels: focus on its association with cardio-cerebrovascular diseases","volume":"79","author":"Li","year":"","journal-title":"J. Physiology Biochem."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.3390\/nu15112609","article-title":"Hydration status in older adults: current knowledge and future challenges","volume":"15","author":"Li","year":"","journal-title":"Nutrients"},{"key":"B2","first-page":"197","article-title":"Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma","volume-title":"Cancer Manag Res,","author":"Macha","year":"2013"},{"key":"B29","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1159\/000531280","article-title":"Clinical characteristics of an Italian patient population with advanced BCC and real-life evaluation of hedgehog pathway inhibitor safety and effectiveness","volume":"239","author":"Mannino","year":"2023","journal-title":"Dermatology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.mcna.2021.05.013","article-title":"Dysphagia and swallowing disorders","volume":"105","author":"Mccarty","year":"2021","journal-title":"Med. Clin. North Am."},{"key":"B31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3928\/00989134-20150814-02","article-title":"Dehydration in the older adult","volume":"41","author":"Miller","year":"2015","journal-title":"J. Gerontol. Nurs."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1158\/1078-0432.CCR-14-3180","article-title":"Management of cutaneous and extracutaneous side effects of smoothened inhibitor therapy for advanced basal cell carcinoma","volume":"21","author":"Mohan","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1001\/jamadermatol.2015.4330","article-title":"Increased risk of cutaneous squamous cell carcinoma after vismodegib therapy for basal cell carcinoma","volume":"152","author":"Mohan","year":"2016","journal-title":"JAMA Dermatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1080\/10408398.2022.2115003","article-title":"The effect of taste on swallowing: a scoping and systematic review","volume":"64","author":"Mulheren","year":"2022","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"B35","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrc3079","article-title":"The Hedgehog\u2019s tale: developing strategies for targeting cancer","volume":"11","author":"Ng","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"7033","DOI":"10.3390\/ijms22137033","article-title":"Molecular and neural mechanism of dysphagia due to cancer","volume":"22","author":"Okuni","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"113254","DOI":"10.1016\/j.ejca.2023.113254","article-title":"European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma\u2014update 2023","volume":"192","author":"Peris","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/mds.10251","article-title":"Cooling improves the writing performance of patients with writer\u2019s cramp","volume":"17","author":"Pohl","year":"2002","journal-title":"Mov. Disord."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e0297531","DOI":"10.1371\/journal.pone.0297531","article-title":"Hedgehog pathway inhibitors for locally advanced and metastatic basal cell carcinoma: a real-world single-center retrospective review","volume":"19","author":"P\u00fcSK\u00fcLL\u00fcO\u011eLU","year":"2024","journal-title":"PLoS One"},{"key":"B40","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1210\/jc.2009-2546","article-title":"Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children","volume":"95","author":"Rivkees","year":"2010","journal-title":"J. Clin. Endocrinol. Metabolism"},{"key":"B41","author":"Roche","year":"2021"},{"key":"B42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrgastro.2015.199","article-title":"Oropharyngeal dysphagia: manifestations and diagnosis","volume":"13","author":"Rommel","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e339","DOI":"10.1111\/jdv.19608","article-title":"Analysis of basal cell carcinomas\u2019 histological subtypes and relative response to vismodegib in six patients diagnosed with Gorlin\u2013Goltz syndrome: a retrospective study","volume":"38","author":"Scotti","year":"","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"453","DOI":"10.23736\/S2784-8671.24.07705-3","article-title":"Efficacy, tolerability, and quality of life evaluation in six patients affected by Gorlin-Goltz syndrome and treated with vismodegib 150 mg\/die: a retrospective monocentric cohort analysis","volume":"159","author":"Scotti","year":"","journal-title":"Italian J. dermatology Venereol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s12885-017-3286-5","article-title":"Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study","volume":"17","author":"Sekulic","year":"2017","journal-title":"BMC Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Sekulic","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/0885-3924(91)90522-6","article-title":"Muscle cramps in the cancer patient: causes and treatment","volume":"6","author":"Siegal","year":"1991","journal-title":"J. Pain Symptom Manag."},{"key":"B49","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/ageing\/30.1.91","article-title":"Diltiazem for nocturnal leg cramps","volume":"30","author":"Voon","year":"2001","journal-title":"Age Ageing"},{"key":"B50","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.1111\/ejn.15799","article-title":"Brain\u2010derived neurotrophic factor overexpression in taste buds diminishes chemotherapy induced taste loss","volume":"56","author":"Vukmanovic Nosrat","year":"2022","journal-title":"Eur. J. Neurosci."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.jaad.2020.02.050","article-title":"Comparison of daily dosing versus Monday through Friday dosing of vismodegib for locally advanced basal cell carcinoma and basal cell nevus syndrome: a retrospective case series","volume":"82","author":"Wong","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"850","DOI":"10.3109\/00498250903180289","article-title":"Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor","volume":"39","author":"Wong","year":"2009","journal-title":"Xenobiotica"},{"key":"B53","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1593\/neo.81264","article-title":"Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2\/BCRP and ABCB1\/Pgp","volume":"11","author":"Zhang","year":"2009","journal-title":"Neoplasia"},{"key":"B54","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41419-023-06270-5","article-title":"Inhibition of Hedgehog signaling ameliorates foam cell formation by promoting autophagy in early atherosclerosis","volume":"14","author":"Zhang","year":"2023","journal-title":"Cell Death Dis."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-025-01896-1","article-title":"Real-world safety of deucravacitinib: insights from the food and drug administration adverse event reporting system","author":"Zhao","year":"2025","journal-title":"Int. J. Clin. Pharm"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1458438","DOI":"10.3389\/fphar.2024.1458438","article-title":"Assessing the real-world safety of tralokinumab for atopic dermatitis: insights from a comprehensive analysis of FAERS data","volume":"15","author":"Zhao","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1158\/0008-5472.CAN-14-2999-T","article-title":"RAS\/MAPK activation drives resistance to smo inhibition, metastasis, and tumor evolution in shh pathway\u2013dependent tumors","volume":"75","author":"Zhao","year":"2015","journal-title":"Cancer Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00280-014-2468-y","article-title":"Absorption, distribution, metabolism, and excretion (ADME) of \u00b9\u2074C-sonidegib (LDE225) in healthy volunteers","volume":"74","author":"Zollinger","year":"2014","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1497708\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T05:20:11Z","timestamp":1747372811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1497708\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":58,"alternative-id":["10.3389\/fphar.2025.1497708"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1497708","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"article-number":"1497708"}}